Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Oct 7;15(12):3015–3027. doi: 10.1158/1535-7163.MCT-16-0017

Figure 3. Cobimetinib treatment inhibits MCL-1 phosphorylation to downregulate expression and induces BIM.

Figure 3

A, RKO cells were treated with increasing doses of cobimetinib for 48 h and protein expression, including BIM isoforms [extra long (EL), long (L) and short (S)] and PARP cleavage (CL), were analyzed by immunboblotting. B, RKO cells were treated with cobimetinib or vemurafenib for the indicated times and expression of pERK/ERK and pMCL-1Thr163/MCL-1 were analyzed by immunoblotting. C, Multiple BRAF mutant CRC cell lines (RKO, HT29, WiDr, VACO432) were treated with cobimetinib at indicated doses for 48 h and protein expression including markers of apoptosis (PARP, caspase-3) were analyzed by immunoblotting. D, RKO BRAF isogenic cell lines with none to two mutant BRAF alleles were treated with cobimetinib vs DMSO and the effect on PARP cleavage was determined.